Related Experiment Video

Updated: Aug 29, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Pharmacotherapy of atrial fibrillation

Ravi R Kasliwal1, Singh Mukesh, Gagan Manohar

  • 1Department of Cardiology, Escorts Heart Institute and Research Centre, Okhla Road, New Delhi 110-025, India. rrkasliwal@hotmail.com

Asian Cardiovascular & Thoracic Annals
|December 19, 2003
PubMed

Insights

Atrial fibrillation (AF) is a common heart rhythm disorder, increasing stroke risk. Management focuses on rate or rhythm control and preventing thromboembolism to reduce patient morbidity and mortality.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is the most prevalent clinically significant sustained arrhythmia, with incidence increasing with age.
  • AF is a major risk factor for thromboembolic events, particularly stroke.
  • Understanding AF etiology, classification, and risk factors is crucial for effective management.

Purpose of the Study:

  • To provide a comprehensive overview of atrial fibrillation management.
  • To compare the efficacy of rate control versus rhythm control strategies in reducing AF-related morbidity and mortality.
  • To review pharmacologic treatments, thromboembolism prevention, and recent therapeutic advances.

Main Methods:

  • Review of existing literature and clinical trials on atrial fibrillation management.
  • Comparative analysis of rate control versus rhythm control strategies.
  • Discussion of pharmacologic agents, their mechanisms, and side effects.
  • Evaluation of thromboembolism prevention and treatment modalities.

Main Results:

  • Both rate and rhythm control strategies aim to improve patient outcomes in atrial fibrillation.
  • Pharmacologic agents vary in their efficacy for rate or rhythm control and carry specific side effect profiles.
  • Thromboembolism prevention is a critical component of AF management, with evolving treatment guidelines.

Conclusions:

  • Optimal management of atrial fibrillation requires a tailored approach considering patient-specific factors.
  • Balancing the benefits and risks of rate versus rhythm control is essential for minimizing morbidity and mortality.
  • Advances in pharmacotherapy and anticoagulation continue to refine the treatment of atrial fibrillation and its complications.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...